Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.680
-0.020 (-2.88%)
At close: Feb 21, 2025, 4:00 PM
0.690
+0.010 (1.46%)
After-hours: Feb 21, 2025, 7:58 PM EST
Ocugen Revenue
Ocugen had revenue of $1.14M in the quarter ending September 30, 2024, a decrease of -69.29%. This brings the company's revenue in the last twelve months to $4.70M, down -33.94% year-over-year. In the year 2023, Ocugen had annual revenue of $6.04M with 142.60% growth.
Revenue (ttm)
$4.70M
Revenue Growth
-33.94%
P/S Ratio
37.96
Revenue / Employee
$72,308
Employees
65
Market Cap
198.48M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
OCGN News
- 1 day ago - Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 10 days ago - Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 19 days ago - Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa - GlobeNewsWire
- 26 days ago - Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 - GlobeNewsWire
- 5 weeks ago - Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - GlobeNewsWire
- 5 weeks ago - Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa - GlobeNewsWire
- 2 months ago - Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 2 months ago - Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - GlobeNewsWire